This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 114/16/1703    most recent CIRCULATIONAHA.106.624320v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, K. W. Articles by Olgin, J. E. Search for Related Content PubMed PubMed Citation Articles by Lee, K. W. Articles by Olgin, J. E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Atrial Fibrillation Heart Failure Related Collections Animal models of human disease Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2006;114:1703-1712.)
© 2006 American Heart Association, Inc.

Heart Failure

Pirfenidone Prevents the Development of a Vulnerable Substrate for Atrial Fibrillation in a Canine Model of Heart Failure

Ken W. Lee, MD, MS; Thomas H. Everett, IV, PhD; Dulkon Rahmutula, MD, PhD; Jose M. Guerra, MD; Emily Wilson, BS; Chunhua Ding, MD, PhD; Jeffrey E. Olgin, MD

From Cardiac Electrophysiology and Cardiovascular Research Institute, University of California, San Francisco, Calif.

Correspondence to Jeffrey E. Olgin, MD, University of California, San Francisco, 500 Parnassus Ave, MU East 4, Box 1354, San Francisco, CA 94143. E-mail olgin{at}medicine.ucsf.edu

Received March 2, 2006; revision received August 16, 2006; accepted August 18, 2006.

Background— Atrial fibrosis is an important substrate in atrial fibrillation (AF), particularly in the setting of structural heart disease. In a canine model, congestive heart failure (CHF) produces significant atrial fibrosis and the substrate for sustained AF. This atrial remodeling is a potential therapeutic target. The objective of the present study is to evaluate the effects of the antifibrotic drug pirfenidone (PFD) on arrhythmogenic atrial remodeling in a canine CHF model.

Methods and Results— We studied 15 canines, divided equally into 3 groups: control, CHF canines not treated with PFD, and CHF canines treated with PFD. CHF was induced by ventricular tachypacing (220 bpm for 3 weeks), and oral PFD was administered for the 3-week pacing period. We performed electrophysiology and AF vulnerability studies, atrial fibrosis measurements, and atrial cytokine expression studies. Only canines in the untreated CHF group developed sustained AF (>30 minutes, 4 of 5 canines; P<0.05). Treatment of CHF canines with PFD resulted in an attenuation of arrhythmogenic left atrial remodeling, with a significant reduction in left atrial conduction heterogeneity index (median [25% to 75% interquartile range] 4.96 [3.53 to 5.64] versus 2.52 [2.11 to 2.82], P<0.01; pacing cycle length 300 ms), left atrial fibrosis (16.0% [13.0% to 17.5%] versus 8.7% [5.7% to 10.6%], P<0.01), and AF duration (1800 [1020 to 1800] seconds versus 6 [5 to 22] seconds, P<0.01). Immunoblotting studies demonstrated the drug’s effects on multiple cytokines, including a reduction in transforming growth factor-ß1 expression.

Conclusions— Treatment of CHF canines with PFD results in significantly reduced arrhythmogenic atrial remodeling and AF vulnerability. Pharmacological therapy targeted at the fibrotic substrate itself may play an important role in the management of AF.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				K. Nishida, G. Michael, D. Dobrev, and S. Nattel Animal models for atrial fibrillation: clinical insights and scientific opportunities Europace, October 29, 2009; (2009) eup328v1. [Abstract] [Full Text] [PDF]

				E. Anter, M. Jessup, and D. J. Callans Atrial Fibrillation and Heart Failure: Treatment Considerations for a Dual Epidemic Circulation, May 12, 2009; 119(18): 2516 - 2525. [Full Text] [PDF]

				R Balasubramaniam and P M Kistler Atrial fibrillation in heart failure: the chicken or the egg? Heart, April 1, 2009; 95(7): 535 - 539. [Abstract] [Full Text] [PDF]

				Z. Lu, B. J. Scherlag, J. Lin, G. Niu, K.-M. Fung, L. Zhao, M. Ghias, W. M. Jackman, R. Lazzara, H. Jiang, et al. Atrial Fibrillation Begets Atrial Fibrillation: Autonomic Mechanism for Atrial Electrical Remodeling Induced by Short-Term Rapid Atrial Pacing Circ Arrhythm Electrophysiol, August 1, 2008; 1(3): 184 - 192. [Abstract] [Full Text] [PDF]

				I. Savelieva and J. Camm Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches Europace, June 1, 2008; 10(6): 647 - 665. [Abstract] [Full Text] [PDF]

				S. Nattel, B. Burstein, and D. Dobrev Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications Circ Arrhythm Electrophysiol, April 1, 2008; 1(1): 62 - 73. [Full Text] [PDF]

				B. Burstein and S. Nattel Atrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation J. Am. Coll. Cardiol., February 26, 2008; 51(8): 802 - 809. [Abstract] [Full Text] [PDF]

				G. Casaclang-Verzosa, B. J. Gersh, and T. S.M. Tsang Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 1 - 11. [Abstract] [Full Text] [PDF]